Evidence map›Paper›PMID 41361014›Full record

ArticleBritish journal of cancer2026

Survival outcomes of ERBB2-amplified metastatic colorectal cancer treated with first-line chemotherapy.

Yuki Matsubara, Hideaki Bando, Yoshiaki Nakamura, Toshihiro Misumi, Dionne Ng, Eri Tajima, Harlan Pittell, Atsushi Ohtsu, Takayuki Yoshino

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuki MatsubaraDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Hideaki BandoDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan. hbando@east.ncc.go.jp.ORCID http://orcid.org/0000-0001-5041-2765
Yoshiaki NakamuraDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.ORCID http://orcid.org/0000-0002-5241-6855
Toshihiro MisumiDivision of Data Science, Department for the Promotion of Drug and Diagnostic Development, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Dionne NgFlatiron Health K.K., Minato-ku, Tokyo, Japan.
Eri TajimaFlatiron Health K.K., Minato-ku, Tokyo, Japan.
Harlan PittellFlatiron Health, Inc., New York, NY, USA.
Atsushi OhtsuThe Cancer Institute of the Japanese Foundation For Cancer Research, Koto-ku, Tokyo, Japan.
Takayuki YoshinoDepartment of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.ORCID http://orcid.org/0000-0002-0489-4756

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHER2-positive or ERBB2 amplified (ERBB2 amp+) metastatic colorectal cancer (mCRC) is an important subgroup due to emerging HER2-targeted therapies. Although ERBB2 amplification is associated with anti-EGFR antibody resistance, optimal first-line treatment remains unclear.

methodsWe analysed data from the Flatiron Health-Foundation Medicine CRC clinico-genomic database, including patients with stage IV or recurrent mCRC diagnosed between January 2012 and March 2022 who underwent tissue-based comprehensive genomic profiling. ERBB2 amp+ was defined as an ERBB2 copy number ≥+3 of the tumour base ploidy.

resultsAmong 5545 patients, 144 (3.1%) had ERBB2 amp+ mCRC. These patients showed significantly worse real-world progression-free survival (rwPFS) than ERBB2 amp- patients (median 7.6 vs. 8.7 months; hazard ratio [HR]: 1.20, 95% confidence interval [CI]: 1.01-1.43, p = 0.04). This trend persisted in patients with left-sided RAS/BRAF V600E wild-type and non-MSI-H mCRC treated with chemotherapy plus anti-EGFR antibody (median 8.7 vs. 12.5 months; HR: 2.18, p = 0.02; adjusted HR: 2.33, p = 0.046) or chemotherapy plus bevacizumab (median 8.9 vs. 10.5 months; HR: 1.65, p = 0.04; adjusted HR: 1.75, p = 0.04). Real-world overall survival did not differ significantly.

conclusionERBB2 amp+ mCRC is a small but clinically relevant subgroup with inferior rwPFS across current first-line treatments, highlighting the need for better strategies.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsErb-b2 Receptor Tyrosine KinasesAdultAgedAged, 80 and overFemaleGene AmplificationHumansMaleMiddle AgedNeoplasm MetastasisProgression-Free SurvivalERBB2 protein, humanErb-b2 Receptor Tyrosine Kinases

Identifiers

PMID41361014
PMCPMC12852667

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.